ストックスクリーナーアプリを入手
75.91
4.48%
-3.58
前日終値:
$79.49
開ける：
$79.62
24時間の取引高:
51,071
Relative Volume:
0.13
時価総額：
$1.11B
収益：
$1.80M
当期純損益:
$1.76B
株価収益率:
0.6397
EPS:
118.674
ネットキャッシュフロー:
$-149.23M
1週間 パフォーマンス:
+5.06%
1か月 パフォーマンス:
-2.76%
6か月 パフォーマンス:
+227.26%
1年 パフォーマンス:
+480.02%
1日の値動き範囲:
$75.49
$79.62
1週間の範囲:
$70.60
$82.16
52週間の値動き範囲:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
名前
Inhibrx Biosciences Inc
セクター
電話
(858) 795-4220
住所
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
INBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
76.01 | 1.16B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.90 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.46 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.39 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.87 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.86 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | 開始されました | JMP Securities | Mkt Perform |
| 2024-01-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 開始されました | SMBC Nikko | Outperform |
| 2021-09-21 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Credit Suisse | Outperform |
| 2020-09-14 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Inhibrx Biosciences Inc (INBX) 最新ニュース
Sell Signal: Is Gorilla Technology Group Inc trading at a discountJuly 2025 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Responsive Playbooks and the INBX Inflection - Stock Traders Daily
Short Interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) Rises By 63.1% - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Nasdaq Futures Science-Driven Path - Kalkine Media
Risk Hedge: Whats the beta of Inhibrx Biosciences Inc stockEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Earnings Risk: Is Inhibrx Biosciences Inc stock a smart buy before Fed meetingJuly 2025 Highlights & Low Risk Profit Maximizing Plans - Bộ Nội Vụ
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.5%What's Next? - MarketBeat
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too (INBX) - Seeking Alpha
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
Is Inhibrx Biosciences Inc. stock attractive for passive investorsJuly 2025 Big Picture & Low Risk High Reward Trade Ideas - Улправда
Is Inhibrx Biosciences Inc. stock dividend yield sustainable2025 Biggest Moves & High Conviction Trade Alerts - Улправда
Can Inhibrx Biosciences Inc. stock deliver surprise earnings beatTake Profit & AI Powered Buy and Sell Recommendations - Улправда
Understanding the Setup: (INBX) and Scalable Risk - Stock Traders Daily
What drives Inhibrx Biosciences Inc stock priceEarnings Per Share Trends & Missed Nvidia? Don’t Miss This One - Early Times
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest - MarketBeat
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts - Insider Monkey
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.2% – Here’s Why - Defense World
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 7.2%Should You Buy? - MarketBeat
Why Inhibrx's Recent Strength May Not Be Built to LastInhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7.9%Here's Why - MarketBeat
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - 富途牛牛
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Why Inhibrx Biosciences Inc. stock could rally in 2025July 2025 Market Mood & Fast Gain Stock Tips - Улправда
Is Inhibrx Biosciences Inc. stock trading at a premium valuation2025 Dividend Review & Low Risk Investment Opportunities - bolumsonucanavari.com
Buyout Rumor: How Inhibrx Biosciences Inc. stock benefits from tech adoptionWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Can Inhibrx Biosciences Inc. stock withstand economic slowdownWeekly Trend Recap & Short-Term Trading Alerts - DonanımHaber
How Inhibrx Biosciences Inc. stock benefits from tech adoptionJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Inhibrx Biosciences Inc. stock deliver consistent dividends2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates - Yahoo Finance
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - Sahm
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - The Malaysian Reserve
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures - Investing.com Canada
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026 - Sahm
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
Inhibrx provides updates on cancer treatment clinical trials - Investing.com
Inhibrx Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
EDGAR Filing Documents for 0002007919-25-000093 - SEC.gov
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Why Is INBX Stock Rising Today? - MSN
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
With Inhibrx Biosciences Stock Surging, Have You Considered The Downside? - Trefis
Inhibrx Biosciences Inc (INBX) 財務データ
収益
当期純利益
現金流量
EPS
3.79%
1.90%
大文字化:
|
ボリューム (24 時間):